NCT06875986 · RECRUITING
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
This study is tracking how Rexulti (brexpiprazole) performs in real-world clinical practice for people with Alzheimer's who show agitation or aggression. It is not a controlled experiment — it is a post-market surveillance survey collecting safety and effectiveness data from patients already being prescribed the drug by their doctors. The phase is unspecified, meaning this is observational, not a traditional drug trial.
Eligibility criteria
Inclusion Criteria: * Patients diagnosed with Alzheimer's disease Exclusion Criteria: -
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-07-02